Takis

🔬 𝙏𝙖𝙠𝙞𝙨 𝘽𝙞𝙤𝙩𝙚𝙘𝙝 𝙚 𝙡𝙖 𝙜𝙚𝙨𝙩𝙞𝙤𝙣𝙚 𝙃𝙍: 𝙪𝙣 𝙘𝙖𝙨𝙤 𝙙𝙞 𝙨𝙪𝙘𝙘𝙚𝙨𝙨𝙤! 🚀 Digitalizzare la gestione del personale può davvero fare la differenza? Takis Biotech ci dimostra con la sua esperienza che non solo è possibile, ma  anche auspicabile! Abbiamo intervistato Monica Fraternali, 𝗛𝗥 𝗦𝘂𝗽𝗲𝗿𝘃𝗶𝘀𝗼𝗿 𝗱𝗶 𝗧𝗮𝗸𝗶𝘀, che ci racconta come è stato possibile ottimizzare i processi interni e migliorare l’esperienza dei dipendenti grazie alla piattaforma semplice e intuitiva di Fluida Europe. 📲 Le 𝗳𝘂𝗻𝘇𝗶𝗼𝗻𝗮𝗹𝗶𝘁𝗮 𝗱𝗶 𝗙𝗹𝘂𝗶𝗱𝗮 𝗛𝗥 𝗦𝘂𝗶𝘁𝗲 che hanno trasformato la loro gestione HR: ✅ 𝗧𝗶𝗺𝗯𝗿𝗮𝘁𝘂𝗿𝗮 𝘀𝗺𝗮𝗿𝘁 e 𝗚𝗲𝘀𝘁𝗶𝗼𝗻𝗲 𝗽𝗿𝗲𝘀𝗲𝗻𝘇𝗲 per avere dati in tempo reale ✅ 𝗡𝗼𝘁𝗮 𝘀𝗽𝗲𝘀𝗲 per una gestione rapida e senza errori ✅ 𝗖𝗼𝗺𝘂𝗻𝗶𝗰𝗮𝘇𝗶𝗼𝗻𝗶 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁𝗶, immediate e senza dispersione di informazioni ✅ 𝗗𝗼𝗰𝘂𝗺𝗲𝗻𝘁𝗶 sempre disponibili, inclusi cedolini e contratti 💡 𝗜𝗹 𝗿𝗶𝘀𝘂𝗹𝘁𝗮𝘁𝗼? Una gestione del personale più strategica e meno burocratica! Grazie alla digitalizzazione, il team ha ridotto il tempo dedicato alla gestione operativa, eliminato errori e migliorato la comunicazione interna. Il tutto con una piattaforma che si integra perfettamente nei loro flussi di lavoro, rendendo la gestione del personale più agile ed efficace. 👇 Leggi l’intervista completa e scopri tutti i dettagli 👇 https://lnkd.in/dzqV4Tcm #HR #digitaltrasformation #employeeexperience #gestionedelpersonale #fluida #TakisBiotech

🔬 Ingegnerizzare i linfociti T direttamente nel corpo dei pazienti: il futuro delle CAR-T? Le terapie CAR-T stanno rivoluzionando l’oncologia, ma la loro produzione resta complessa e costosa. La soluzione? Generarle direttamente nel paziente, trasformandolo in una “bio-officina”. Una review su Journal of Translational Medicine dei ricercatori della biotech italiana Takis analizza le strategie per superare i limiti attuali e rendere queste terapie più accessibili ed efficaci. Ce ne parla Eleonora Pinto, ricercatrice presso Takis e prima autrice della review. 👉 https://lnkd.in/dD43tZkn

At Takis Biotech, we are committed to developing next-generation #antibody #therapies to combat infectious diseases. Our 9-8F2-B11 and 3-12B12-F4 monoclonal antibody combination has been designed to maximize neutralization potential against SARS-CoV-2 variants, providing a powerful tool in the fight against COVID-19. By leveraging cutting-edge biotechnology, we aim to enhance efficacy and adaptability, ensuring robust protection against emerging viral mutations. If you want to develop custom antibodies, we are the right partner for you! Send us a message here on LinkedIn to discover how we operate.

Meet Cristina Nardacci, our dedicated Expert Accountant and Purchaser Executive at Takis! Since joining Takis in September 2020, Cristina N. has played a key role in managing commercial operations, seamlessly coordinating with clients and suppliers. Her expertise ensures smooth financial transactions and efficient procurement processes. Beyond her commercial role, Cristina oversees import-export activities and provides comprehensive administrative support, ensuring that all operations run efficiently. We are proud to have Cristina on our team and appreciate her invaluable contributions!

Innovation is in our #DNA… literally! 🧬 Let’s dive in the discovery of our X-eVax Technology Platform Service! X-eVax stands for "Antigen X" + "e-Vax" (electroporation delivery). It's a next-gen vaccine platform designed to trigger a powerful immune response while minimizing side effects. Discover how its process works and what makes it a reliable and innovative platform!

We are proud to announce the appointment of our CTO Giuseppe Roscilli to the Scientific Council of Rome Technopole! This is an important recognition for his contribution in the field of biotechnology and innovation. His expertise will be instrumental in promoting the research and development of cutting-edge solutions in oncology, immunology and vaccination. This appointment further strengthens our commitment to the Rome Technopole, an ecosystem of excellence that brings together companies, universities and institutions to accelerate scientific and technological progress. Congratulations to Giuseppe for this prestigious appointment!

At Takis, we believe that innovation is strictly related to the people. Here are some words from our COO, Emanuele Marra, on this topic: "The true strength of any company lies in its people. At Takis, we nurture talent, encourage collaboration, and empower our team to turn ideas into impactful solutions. Every breakthrough we achieve stems from the dedication and creativity of those who work with us." Our commitment goes beyond research: we invest in our team, creating an environment where talent can flourish, and every voice is valued. Let’s continue building a culture of growth, respect, and excellence as we push boundaries and transform ideas into reality. Together, we are making a difference!

Yesterday, we were honored to host the General Director and the European Project Design Services team from Rome Technopole, the regional innovation ecosystem, at our headquarters. As co-leaders of Flagship Project 7, Takis plays a pivotal role in driving the development of advanced laboratories for diagnostic and therapeutic biopharmaceutical solutions. This project is a key initiative to foster cutting-edge research and innovation in biotechnology, strengthening Rome's position as a hub for scientific and healthcare advancements. During the visit, we showcased our expertise in innovative delivery platforms, regulating gene activity, and enhancing immune responses, highlighting how our technologies are advancing the fields of vaccines, monoclonal antibodies, and therapies targeting tumor antigens involved in cancer progression as well as infectious diseases. At Takis, our mission is to develop therapeutic vaccines and monoclonal antibodies to combat both cancer and infectious diseases, while fostering strong partnerships with academia, industry, and public institutions. Through our leadership in Flagship Project 7, we aim to shape the future of healthcare innovation not only regionally but across Europe.

🎥 MIRIA Project: Meet Our Partners! 🌟 We’re excited to present a new video in our series, highlighting the incredible partners of the MIRIA project! 🎉 📍 In this episode, we introduce Takis, a leading biotechnology company based in Rome. 🧬as a key partner of the MIRIA project. TAKIS is focused on evaluating the antiviral properties of nanocoatings by measuring the residual infectivity of various viruses on eukaryotic cells after prolonged incubation with coated or uncoated materials. 🔬 Through collaboration with other project partners, TAKIS is studying how the nanocoatings developed can neutralize viruses, enhancing safety and protection in healthcare environments and beyond. This is a crucial step toward a safer future! 🔍 Want to learn more about TAKIS’ contributions and how they’re helping to shape the future of nanotechnology? Stay tuned as we continue to share updates on our groundbreaking work! 💬 Share your thoughts with us in the comments and don’t forget to follow us for more exciting updates! #MIRIAProject #TAKIS #Biotechnology #Nanotechnology #AntiviralResearch #Nanocoatings #HealthInnovation #FutureOfHealthcare #SafeMaterials #ResearchAndDevelopment #InnovationInScience #HealthcareSafety #TechForGood #Sustainability #VirusNeutralization #BiotechInnovation

At Takis, we specialize in producing highly pure, stable mRNA designed for optimal translation efficiency! Our expertise and streamlined processes ensure reliable results across every step of the end-to-end mRNA production workflow. Its purity, scalable production and quality control assay, make our mRNA solutions ideal for diverse applications, including basic research, vaccine development, and gene therapy studies, particularly in preclinical phases. Are you curious? Discover more about our mRNA production in the following carousel! Reach out to learn how we can tailor our services to your needs.